| Literature DB >> 28501093 |
Abstract
"This issue of Hematology/Oncology Clinics of North America provides an update to the current understanding of the physiology of gastric and esophageal cancers and the state-of-the-art management of disease. Over the past 10 years, we have witnessed dramatic changes in both our understanding of the disease and its management. We have 2 new biological agents approved to treat advanced disease, with several more prospects under development. In this article, the author looks to the future, attempting to answer the question of which advancements will play the biggest role in improving patient outcomes in this still-devastating disease.Entities:
Keywords: Epidemiology; Helicobacter pylori; Locally advanced disease; Molecular profiling; Targeted therapy
Mesh:
Substances:
Year: 2017 PMID: 28501093 DOI: 10.1016/j.hoc.2017.01.010
Source DB: PubMed Journal: Hematol Oncol Clin North Am ISSN: 0889-8588 Impact factor: 3.722